阿非利西普与雷尼单抗治疗期间的肾损伤：一项基于人群的研究。

IF 2.1 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-09-03 DOI:10.1097/IAE.0000000000004653

Robert J Campbell, Sherif R El-Defrawy, Sudeep S Gill, Jonas Shellenberger, Marlo Whitehead, Chaim M Bell, Susan E Bronskill, J Michael Paterson, Michael A McIsaac

{"title":"阿非利西普与雷尼单抗治疗期间的肾损伤：一项基于人群的研究。","authors":"Robert J Campbell, Sherif R El-Defrawy, Sudeep S Gill, Jonas Shellenberger, Marlo Whitehead, Chaim M Bell, Susan E Bronskill, J Michael Paterson, Michael A McIsaac","doi":"10.1097/IAE.0000000000004653","DOIUrl":null,"url":null,"abstract":"Purpose: Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal VEGF levels than ranibizumab. We compared the risk of kidney injury among patients receiving intravitreal aflibercept vs. ranibizumab.Methods: This population-based new-user active-comparator cohort study in Ontario, Canada, evaluated 44,571 patients aged 66 years and older, newly treated with intravitreal aflibercept or ranibizumab between August 1, 2015, and July 31, 2019. The risk of adverse renal outcomes was compared while controlling for baseline and time-varying covariates.Results: The composite renal outcome occurred in 12.0% (1,778/14,863) of aflibercept recipients versus 10.0% (1,327/13,289) of ranibizumab recipients (Relative risk: 1.00, 95% CI: 0.93-1.06 at 5 years follow up). No significant differences were observed across retinal disease subgroups.Conclusion: Intravitreal aflibercept and ranibizumab carry comparable risks of renal adverse events despite their distinct systemic pharmacodynamics.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Kidney Injury During Treatment with Aflibercept versus Ranibizumab: a Population-based Study.\",\"authors\":\"Robert J Campbell, Sherif R El-Defrawy, Sudeep S Gill, Jonas Shellenberger, Marlo Whitehead, Chaim M Bell, Susan E Bronskill, J Michael Paterson, Michael A McIsaac\",\"doi\":\"10.1097/IAE.0000000000004653\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal VEGF levels than ranibizumab. We compared the risk of kidney injury among patients receiving intravitreal aflibercept vs. ranibizumab.Methods: This population-based new-user active-comparator cohort study in Ontario, Canada, evaluated 44,571 patients aged 66 years and older, newly treated with intravitreal aflibercept or ranibizumab between August 1, 2015, and July 31, 2019. The risk of adverse renal outcomes was compared while controlling for baseline and time-varying covariates.Results: The composite renal outcome occurred in 12.0% (1,778/14,863) of aflibercept recipients versus 10.0% (1,327/13,289) of ranibizumab recipients (Relative risk: 1.00, 95% CI: 0.93-1.06 at 5 years follow up). No significant differences were observed across retinal disease subgroups.Conclusion: Intravitreal aflibercept and ranibizumab carry comparable risks of renal adverse events despite their distinct systemic pharmacodynamics.\",\"PeriodicalId\":54486,\"journal\":{\"name\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IAE.0000000000004653\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004653","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：系统应用抗癌VEGF抑制疗法可引起严重的肾损伤。玻璃体内注射阿非利西普对肾脏VEGF水平的影响比雷尼单抗更大。我们比较了玻璃体内注射阿非利西普和雷尼单抗患者肾损伤的风险。方法：这项基于人群的新用户活跃比较队列研究在加拿大安大略省进行，评估了44,571名年龄在66岁及以上的患者，这些患者在2015年8月1日至2019年7月31日期间接受了玻璃体内阿非利塞普或雷尼单抗的新治疗。在控制基线和时变协变量的情况下，比较肾脏不良结局的风险。结果：复合肾结局发生在12.0%（1778 / 14863）的阿非利西ept接受者和10.0%（1327 / 13289）的雷尼单抗接受者（相对风险：1.00,95% CI: 0.93-1.06）。视网膜疾病亚组间无显著差异。结论：尽管阿非利西贝和雷尼单抗的全身药效学不同，但玻璃体内注射阿非利西贝和雷尼单抗的肾脏不良事件风险相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Kidney Injury During Treatment with Aflibercept versus Ranibizumab: a Population-based Study.

Purpose: Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal VEGF levels than ranibizumab. We compared the risk of kidney injury among patients receiving intravitreal aflibercept vs. ranibizumab.

Methods: This population-based new-user active-comparator cohort study in Ontario, Canada, evaluated 44,571 patients aged 66 years and older, newly treated with intravitreal aflibercept or ranibizumab between August 1, 2015, and July 31, 2019. The risk of adverse renal outcomes was compared while controlling for baseline and time-varying covariates.

Results: The composite renal outcome occurred in 12.0% (1,778/14,863) of aflibercept recipients versus 10.0% (1,327/13,289) of ranibizumab recipients (Relative risk: 1.00, 95% CI: 0.93-1.06 at 5 years follow up). No significant differences were observed across retinal disease subgroups.

Conclusion: Intravitreal aflibercept and ranibizumab carry comparable risks of renal adverse events despite their distinct systemic pharmacodynamics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.